2021
Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant
Johnston JP, Cohen EA, Casal GH, Asch WS, Reardon DP. Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant. Journal Of Pharmacy Practice 2021, 35: 701-706. PMID: 33759619, DOI: 10.1177/08971900211000702.Peer-Reviewed Original ResearchConceptsLow-dose fluconazoleRenal transplant patientsAdverse drug reactionsTAC levelsTransplant patientsGraft rejectionDrug reactionsTherapeutic levelsSingle-center retrospective chart reviewPost-operative day 10Azole antifungal therapySubtherapeutic tacrolimus levelsTAC dose adjustmentRenal transplant recipientsTotal daily doseRetrospective chart reviewTacrolimus dosingTacrolimus levelsRenal transplantTransplant recipientsChart reviewSecondary outcomesDaily doseDose adjustmentPrimary outcomeEffect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis
Sevransky J, Rothman R, Hager D, Bernard G, Brown S, Buchman T, Busse L, Coopersmith C, DeWilde C, Ely E, Eyzaguirre L, Fowler A, Gaieski D, Gong M, Hall A, Hinson J, Hooper M, Kelen G, Khan A, Levine M, Lewis R, Lindsell C, Marlin J, McGlothlin A, Moore B, Nugent K, Nwosu S, Polito C, Rice T, Ricketts E, Rudolph C, Sanfilippo F, Viele K, Martin G, Wright D, Nugent K, Spainhour C, Polito C, Moore B, Negrin L, Khan A, Kea B, Krol O, Haq E, Pinkert V, Nguyen K, Brown S, Bledsoe J, Peltan I, Applegate D, Armbruster B, Montgomery Q, Brown K, Daw A, Gong M, Aboodi M, Chen J, Hope A, Gummadi S, Lopez B, Hinson J, Hager D, Ricketts E, Clements C, Gajic O, Kashyap R, Vanmeter D, Busse L, McBride M, Ginde A, Moss M, Finck L, Howell M, McKeehan J, Higgins C, Clare J, McBryde B, Barksdale A, Kalin D, Kruse D, Hilz K, Qadir N, Chang S, Beutler R, Tam A, Harris E, Youngquist S, Middleton E, Davidov E, Plante A, Belsky J, Siner J, Wira C, Brokowski C, Steingrub J, Smithline H, Thornton-Thompson S, Fowler A, Miller S, Narron K, Puskarich M, Prekker M, Hendrickson A, Quinn J, Wilson J, Levitt J, Mann R, Visweswaran A, Gentile N, Marchetti N, Reimer H, Guirgis F, Jones L, Black L, Henson M, Meyer N, Greenwood J, Ittner C, Rivers E, Jayaprakash N, Gardner-Gray J, Hurst G, Pflaum J, Jaehne A, Gill J, Cook A, Janz D, Vonderhaar D, Romaine C, Wilkerson R, McCurdy M, Beach D, Lasko K, Gill R, Price K, Dickson L, Duggal A, Mace S, Hite R, Hastings A, Haukoos J, Douglas I, Trent S, Lyle C, Cupelo A, Gravitz S, Hiller T, Oakes J, LoVecchio F, Quiroga P, Danley S, Mulrow M, Encinas A, Goodwin A, Hall G, Grady A, Exline M, Terndrup T, Pannu S, Robart E, Karow S, Files D, Smith L, Gibbs K, Flores L, Pastores S, Shaz D, Kostelecky N, Case C, Wilkins E, Gaieski D, Baram M, Schwegler D, Renzi N, Mosier J, Hypes C, Campbell E, Hooper M, Sill J, Mitchell K, Hudock K, Lyons M, Gorder K, Ahmad Y, Studer A, Davis J, Barrett M, Nomura J, Knox J, Park P, Co I, McSparron J, Hyzy R, McDonough K, Hanna S, Self W, Semler M, Hays M, Bartz R, Limkakeng A, Sweeney K, Woodburn R, Goyal M, Zaaqoq A, Moriarty T, Oropello J, Zhang Z. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. JAMA 2021, 325: 742-750. PMID: 33620405, PMCID: PMC7903252, DOI: 10.1001/jama.2020.24505.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory AgentsAscorbic AcidCritical IllnessDouble-Blind MethodDrug Therapy, CombinationEarly Termination of Clinical TrialsFemaleHumansHydrocortisoneLength of StayMaleMiddle AgedOrgan Dysfunction ScoresRespiration, ArtificialRespiratory InsufficiencySepsisThiamineTreatment OutcomeVasoconstrictor AgentsVitaminsConceptsVasopressor-free daysIntensive care unitVitamin CPlacebo groupCare unitIntervention groupDays of randomizationIntravenous vitamin CPlacebo-controlled trialThirty-day mortalityTotal daily doseKey secondary outcomesAdult patientsSecondary outcomesDaily doseIll patientsPrimary outcomeSubstantial morbidityCardiovascular dysfunctionEmergency departmentCommon syndromeMAIN OUTCOMESepsisPlaceboPatientsBXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).
Aggarwal R, Costin D, Zhang J, Karsh L, Healey D, Linch M, Adurthi S, Petrylak D, O'Neill V, Monk P. BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2021, 39: 124-124. DOI: 10.1200/jco.2021.39.6_suppl.124.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTotal daily doseAdverse eventsPhase 2 portionObjective responseImproved tolerabilityAnti-PD-1/PD-L1Day 1Serum IL-18 levelsCastration-resistant prostate cancerOral small-molecule inhibitorDipeptidyl peptidasePreliminary anti-tumor activityPhase 2 doseAndrogen deprivation therapyCytokine release syndromeStage IV melanomaIL-18 levelsPD-L1 expressionSignificant tumor growth inhibitionLower extremity edemaImmune effector cellsPrior clinical studiesTarget adverse eventsProstate cancer phenotype
2015
Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial
Rostaing L, Bunnapradist S, Grinyó J, Ciechanowski K, Denny J, Silva H, Budde K, Group E, Denny J, Kulkarni S, Hricik D, Bresnahan B, Bunnapradist S, El-Sabrout R, Chan L, Ciancio G, El-Ghoroury M, Goldstein M, Gaston R, Gohh R, Killackey M, King A, Knight R, Kore A, Sudan D, Friedmann J, Mulgaonkar S, Nolan C, Pankewycz O, Pirsch J, Schaefer H, Steinberg S, Gelb B, True K, West-Thielke P, Waybill M, Wolf J, Ketel B, Harland R, Shihab F, Cassuto E, Le Meur Y, Rostaing L, Mariat C, Grinyó J, Puig J, Seron D, Tisone G, Ciechanowski K, Foroncewicz B, Wlodarczyk Z, Budde K, Witzke O, Mondragon G, Urrea E, Gomez J, Acevedo R, del Carmen Rial M, Novoa P, Silva H, Garcia V, Carvalho D, Saber L, Contieri F, Bastos M, Manfro R, Kanellis J, Eris J, O’Connell P, Hughes P, Russ G, Pidgeon G, Dittmer I, Kee T, Vathsala A, Naumovic R, Mitic I, Parmjeet R. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal Of Kidney Diseases 2015, 67: 648-659. PMID: 26717860, DOI: 10.1053/j.ajkd.2015.10.024.Peer-Reviewed Original ResearchConceptsTotal daily doseDe novo kidney transplant recipientsNovo kidney transplant recipientsKidney transplant recipientsIR-TacKidney transplantationTransplant recipientsAdverse eventsTreatment failureDaily extended-release tacrolimusDe novo kidney transplantationMean total daily doseLower total daily doseExtended-release tacrolimusOnce-Daily ExtendedTarget trough rangesTwice-Daily TacrolimusNew-onset diabetesSafety end pointSerious adverse eventsPhase 3 trialImmediate-release tacrolimusParticipant eligibility criteriaTwo-year resultsImproved bioavailability
2011
Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease
Pashankar F, Manwani D, Lee M, Green N. Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease. Blood 2011, 118: 4841. DOI: 10.1182/blood.v118.21.4841.4841.Peer-Reviewed Original ResearchTricuspid regurgitant jet velocityElevated pulmonary artery pressurePulmonary artery pressureSickle cell diseaseArtery pressureCell diseaseEffect of hydroxyureaPulmonary hypertensionElevated tricuspid regurgitant jet velocityWhite blood cell countMean reticulocyte countTotal daily doseRegurgitant jet velocityRole of inflammationMean oxygen saturationBlood cell countFetal hemoglobinMean corpuscular volumeRepeat echocardiogramAverage followEndothelial dysfunctionDaily doseEndothelial functionPersistent elevationMean age
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply